oral semaglutide novo US FDA accepts Nordisk's application for Wegovy for weight loss Novo Nordisk has announced that

Dose adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia [see WARNINGS AND PRECAUTIONS ]

Investigational New Drug Application (IND): If preclinical results are promising, the sponsor submits an IND application to the FDA, detailing the drug's composition, manufacturing, and proposed clinical trials

The severity depends on how intensely the immune system reacts and whether it produces specific antibodies against the compound

Helps improve body composition

Additionally, it may not be prescribed in cases of severe gastrointestinal disorders as it may affect the digestive system

Both the 2016 consensus statement of the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) on management of type 2 diabetes and the 2016 American Diabetes Association (ADA) standards recommend adding on GLP-1 RAs to patients not meeting treatment goals with basal insulin